Journal of public health research · 2026
Parkinson's disease mortality and years of potential life lost in Iran: A 10-year national analysis (2013-2023).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sadeghzadeh Faezeh, Sahebi Mahdieh, Ghavami Mahin, Kazemi Elaheh, Etemadi Hamed, Nezamdoust Fatemeh Zahra, Mosa Farkhani Ehsan
Аннотация
BACKGROUND: Parkinson's disease (PD) is a leading neurodegenerative disorder associated with increasing global morbidity and premature mortality. Despite its growing burden, national trends in PD-related mortality and years of potential life lost (YPLL) remain understudied in Iran.
OBJECTIVES: To examine temporal trends in PD-related mortality and YPLL in Iran from 2013 to 2023 and to assess demographic and regional disparities.
METHODS: This repeated cross-sectional study used data from the Iranian National Death Registration System. All deaths attributed to PD (ICD-10 codes G20 and G21) between 2013 and 2023 were included. Crude age-specific and cause-specific mortality rates were calculated, and YPLL was estimated using standard methods. Temporal trends were assessed using regression-based analyses. Spatial patterns were evaluated using ArcGIS, and statistical analyses were performed in Stata version 17.
RESULTS: A total of 9229 PD-related deaths were recorded. Crude mortality rates increased from 0.21 per 100,000 in 2013 to 1.77 in 2023, while YPLL rose from 1.21 to 7.86 per 100,000. Males consistently exhibited higher mortality and YPLL than females. Geospatial analysis identified higher burdens in Tehran, Khorasan Razavi, Isfahan, and Fars. Lower rates in several rural provinces may partly reflect underreporting or disparities in healthcare access.
CONCLUSION: The observed increase in crude PD-related mortality and YPLL over the past decade suggests a growing public health challenge in Iran. However, these trends should be interpreted with caution, as they may be influenced by population aging, improvements in diagnosis, and changes in death registration practices. Strengthening early diagnosis, specialized care, and equitable access to neurological services-particularly in underserved regions-remains a public health priority.
OBJECTIVES: To examine temporal trends in PD-related mortality and YPLL in Iran from 2013 to 2023 and to assess demographic and regional disparities.
METHODS: This repeated cross-sectional study used data from the Iranian National Death Registration System. All deaths attributed to PD (ICD-10 codes G20 and G21) between 2013 and 2023 were included. Crude age-specific and cause-specific mortality rates were calculated, and YPLL was estimated using standard methods. Temporal trends were assessed using regression-based analyses. Spatial patterns were evaluated using ArcGIS, and statistical analyses were performed in Stata version 17.
RESULTS: A total of 9229 PD-related deaths were recorded. Crude mortality rates increased from 0.21 per 100,000 in 2013 to 1.77 in 2023, while YPLL rose from 1.21 to 7.86 per 100,000. Males consistently exhibited higher mortality and YPLL than females. Geospatial analysis identified higher burdens in Tehran, Khorasan Razavi, Isfahan, and Fars. Lower rates in several rural provinces may partly reflect underreporting or disparities in healthcare access.
CONCLUSION: The observed increase in crude PD-related mortality and YPLL over the past decade suggests a growing public health challenge in Iran. However, these trends should be interpreted with caution, as they may be influenced by population aging, improvements in diagnosis, and changes in death registration practices. Strengthening early diagnosis, specialized care, and equitable access to neurological services-particularly in underserved regions-remains a public health priority.